diabetes patients

New research into diabetes suggests that keeping blood sugar levels extremely stable may come at a cost, challenging the assumption that tighter control is always better for patients. The findings are drawing attention among clinicians and people managing diabetes, who are weighing what the results could mean for treatment targets and everyday glucose management advice.

A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.

An obesity medicine doctor is addressing the growing trend of microdosing Ozempic, the diabetes drug widely used for weight loss, explaining the safety concerns and potential risks of taking lower-than-standard doses. The doctor notes there are limited situations where a low dose may be appropriate, but warns patients against adjusting medication on their own without medical supervision.

Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic may face heightened health risks during the current heat wave. Concerns center on dehydration, as the medications can suppress thirst and appetite, potentially leaving users vulnerable to heat exhaustion and related complications. Patients are being advised to drink water regularly and take precautions in high temperatures as extreme heat persists across many regions.

The FDA has approved Onswik, a once-weekly insulin intended for adults with type 2 diabetes. It was not approved for type 1 diabetes. Coverage highlights what the clinical trials showed about effectiveness and the side effects patients should know about. The approval is drawing attention as a potential convenience shift for diabetes management, reducing injections from daily to weekly.

A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.

New coverage reports that heart and kidney complications in patients with type 2 diabetes increase as the disease progresses over time. The finding underscores the cumulative toll of diabetes on cardiovascular and renal health and highlights the importance of long-term monitoring and management of blood sugar, blood pressure and kidney function in affected patients.

The American Diabetes Association has released new guidance aimed at helping primary care providers use diabetes technology, such as continuous glucose monitors and insulin delivery systems, in everyday patient care. The move reflects how these tools are shifting from specialist settings into general practice, and clinicians are expected to review the recommendations for managing patients with diabetes.

A new report finds that 12.4% of teenagers taking GLP-1 weight-loss and diabetes medications are diagnosed with vitamin D deficiency within a year, and few of them receive nutrition counseling to offset the risk. The findings raise concerns about whether young patients on these increasingly prescribed drugs are getting adequate dietary support alongside treatment.